Clinical and Vaccine Immunology · 2011 · 332 citations · 18 references
Life SciencesMolecular BiologyPediatricsMolecular VirologyPediatric ImmunologyVirologyNeonatal ImmunologyViral InfectionsAdeno-associated Viral VectorsAdeno-associated Virus SafetyAdenoviral VectorsAdenovirus BiologyAdenovirus VectorsResearch With Human Subjects
Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.
18
Sylvie Boutin, Virginie Monteilhet, P. Véron et al. · Human Gene Therapy · 2010 · 947 citations
Haiyan Jiang, Linda B. Couto, Susannah Patarroyo‐White et al. · Blood · 2006 · 320 citations · Full text
Pharmacy, Genetics, Immunology +17
Andrew M. Davidoff, John T. Gray, Catherine Y. Ng et al. · Molecular Therapy · 2005 · 216 citations · Full text